Physician profile
Robert James Gallo
NPI 1750385225
$721.11
in general payments reported to CMS, 2019-2025
17 companies · $14.13 in 2025
The $14.13 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $83.66 · 2021: $342 · 2022: $63.64 · 2023: $33.62 · 2024: $20.33 · 2025: $14.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $68.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $68.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| C. R. Bard, INC. & Subsidiaries | $205.00 | 2021 | |
| Lupin INC. | $72.08 | 2019-2020 | |
| Exeltis, USA INC. | $67.37 | 2019-2022 | |
| Avion Pharmaceuticals | $64.87 | 2019-2023 | Balcoltra |
| Pfizer INC. | $44.46 | 2019-2022 | |
| Agile Therapeutics, INC. | $42.50 | 2021 | |
| Mayne Pharma Commercial LLC | $29.72 | 2021 | |
| Daiichi Sankyo INC. | $28.68 | 2021-2022 | |
| Abbvie INC. | $28.00 | 2019 | |
| Vertical Pharmaceuticals, LLC | $26.59 | 2019 | |
| Becton, Dickinson and Company | $20.33 | 2024 | Bd Onclarity |
| Astellas Pharma US INC | $19.77 | 2023 | Veozah |
| Allergan, INC. | $17.62 | 2019 | |
| Novo Nordisk INC | $14.13 | 2025 | Wegovy |
| Therapeuticsmd, INC. | $13.80 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $13.36 | 2021 | |
| Merck Sharp & Dohme LLC | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gallo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.